3 news items
Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study
ANNX
4 Jun 24
-day reduction in the median time to walk independently versus placebo.
ANX005 also provided an early reduction in the prespecified analysis
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
ANNX
7 May 24
and eight million people globally, severely limiting their independence and causing frustration, anxiety and emotional hardship. Effective treatments
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
ANNX
1 May 24
, severely limiting their independence and causing frustration, anxiety and emotional hardship. Effective treatments that preserve vision are still
- Prev
- 1
- Next